CapsoVision, Inc. Honored by Frost & Sullivan for Ongoing Technology Advancement and Market Growth in the Capsule Endoscopy MarketMay 19, 2016CapsoVision, Inc., a Silicon Valley medical device innovator, announces that they have been recognized by Frost & Sullivan as the recipient of the 2016 European Enabling Technology Leadership award. CapsoVision had previously been awarded by Frost & Sullivan for excellence in product differentiation in 2013.
- March 4, 2016CapsoVision is pleased to announce it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for CapsoCam® SV-1. The clinical study submitted to the FDA was designed to demonstrate that CapsoCam SV-1 is safe and effective for the intended use of visualization of the small bowel mucosa in adults, and it may be used as a tool in the detection of abnormalities of the small bowel The study compared CapsoCam SV-1 to PillCam® SB2. Results from the multi-center study demonstrate that CapsoCam SV-1 performs in a manner that is substantially equivalent to PillCam SB2 and has a comparable safety profile as PillCam SB2. In a patient questionnaire administered during the study, ~80% patients indicated that they preferred the CapsoCam system to the PillCam system.
- February 29, 2016
SARATOGA, Calif. - February 29, 2016 - CapsoVision, Inc., a Silicon Valley medical device innovator, announces availability of their next generation small bowel capsule endoscopy solution, The CapsoCam® Plus System.
The CapsoCam Plus System consists of a capsule endoscope, a retrieval kit, a data access system, and software, which work together to provide a streamlined, patient-friendly examination with no capital investment required.